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Abstract  
Identification of new psychoactive substances (NPS) is challenging. Developing targeted 
methods for their analysis can be difficult and costly due to their impermanence on the drug 
scene. Accurate mass-mass spectrometry (AMMS) using a quadrupole time-of-flight (QTOF) 
analyzer can be useful for wide-scope screening since it provides sensitive, full-spectrum MS 
data.  
Our article presents a qualitative screening workflow based on data-independent acquisition 
mode (All-ions MS/MS) on liquid chromatography (LC) coupled to QTOFMS for the 
detection and identification of NPS in biological matrices. The workflow combines and 
structures fundamentals of target and suspect screening data processing techniques in a 
structured algorithm. This allows the detection and tentative identification of NPS and their 
metabolites.  
We have applied the workflow to two actual case studies involving drug intoxications where 
we detected and confirmed the parent compounds ketamine, 25B-NBOME, 25C-NBOMe and 
several predicted Phase I and II metabolites not previously reported in urine and serum 
samples. The screening workflow demonstrates the added value for the detection and 
identification of NPS in biological matrices. 
 
Keywords: designer drugs, All-Ions MS/MS, LC-QTOFMS, 25B-NBOMe, suspect 
screening, qualitative screening 
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Introduction  
Liquid chromatography (LC) coupled to accurate-mass mass spectrometry (AMMS) based on 
a quadrupole time-of-flight (QTOF) provides sensitive full-spectrum MS data for the 
identification of known and previously unknown compounds [1-3]. Several applications 
using LC-QTOFMS have been reported in the literature for the screening of many different 
families of compounds in biological samples [4-7]. 
While AMMS in full-acquisition mode provides meaningful information for the 
characterization of unknowns in complex samples (molecular formula, isotopic patterns, 
double bond equivalents (DBE)), MS/MS fragment ions are normally required for a tentative 
structural elucidation. In this regard, several approaches can be applied to conduct MS/MS 
experiments. The data-dependent acquisition mode presents an advantage as it allows getting 
accurate mass information on both the precursor ion and its product ions (MS and MS/MS) in 
a single injection. However, MS/MS information for the less abundant ions is very often lost, 
since acquisition of MS/MS is triggered by the detection of ions above a certain threshold.  In 
addition, the maximum number of precursors selected per cycle and active exclusion for 
compounds overlapping or with close retention time can affect acquisition of MS/MS spectra. 
Therefore, additional injections in targeted MS/MS would be required. Novel acquisition 
modes are available in more recent high-resolution/accurate-mass (HRAM) instruments, 
which aim to increase the throughput of unknown identification. 
In data-independent acquisition mode, all ions are fragmented without a specific isolation of a 
precursor ion in the first mass analyzer [8-10]. This mode is also known as MS
E
, All Ions 
MS/MS or all-ion fragmentation (depending on the manufacturer). In a single injection, 
different collision energies can be  applied, providing accurate fragmentation spectra for each 
‘precursor ion’ [2,11]. This acquisition mode has been proven ideal for qualitative purposes 
and allows for retrospective analysis using the accurate mass full-acquisition and ‘MS/MS’ 
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information even years after data are acquired [12]. In addition, there exist a variety of 
sophisticated data processing approaches that utilize advanced software programmes, which 
can be applied  depending on the goals of the research and tools available [8].  
One data processing approach for the identification of compounds is ‘Suspect screening’ and 
has been described by some researchers [3,13-15]. It involves extraction of the exact masses 
(calculated based on molecular formula) of expected ions [M+H]
+
 or [M−H]− from the 
acquired data [3]. It relies on the information of the molecular formula and structure for the 
tentative identification of compounds present in a sample and can be useful when no 
reference standards are available to confirm mass spectra and retention time information. 
However, in ‘Target screening’ - another data processing approach, a reference standard is 
required to match measured retention time and MS/MS spectrum [3,16]. 
The different advantages of  these data processing approaches makes it very attractive to 
apply them for the detection and tentative identification of new psychoactive substances 
(NPS). NPS are an interesting group of compounds that mimic effects of illicit drugs like 
cocaine, cannabis and amphetamines but evade law enforcement by introducing slight 
modifications to chemical structures of controlled substances. NPS are easily acquired legally 
through online vendors and smart shops where they are sold under false labels with 
misleading information about their effects and safety. They are considered a growing 
problem in many communities and are responsible for numerous fatal intoxications [17,18]. 
There are currently around 450 NPS being monitored in the market [18], but not much is 
known about their actual use. The detection of NPS is challenging due to their rapid 
transience on the drug scene creating a scenario with constantly moving analytical targets.  
Furthermore, there is limited experimental data on their pharmacokinetics and 
biotransformation pathways [19]. It is therefore difficult to determine target NPS biomarkers 
for further analysis. In addition, the reference standards of NPS and their metabolites are 
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often costly and not always available. Taking this into account a suspect screening based on 
AMMS data would be a good approach to determine their occurrence prior to purchasing 
expensive reference standards for experimental analysis.  
Several studies have used AMMS techniques to characterize NPS in various samples [13,20-
22]. However, most studies have focused on target screening of NPS, with available reference 
standards. Furthermore, only one study at this point [13] has applied a suspect screening 
approach and detailed their sophisticated data processing techniques, showing their 
contribution to compound identification of NPS.  
 
In this work, we combine and structure fundamentals of suspect and targeted screening data 
processing techniques. The aims were to i) develop a robust workflow for the analysis of NPS 
in biological samples using AMMS data, acquired through data-independent acquisition 
mode; ii) provide structured detail into how to process and handle the data acquired; iii) 
demonstrate the advantages and application of this workflow in the identification of co-
eluting and isomeric compounds; and iv) discuss challenges and complications related to the 
workflow by demonstrating the feasibility of its application. 
 
Materials and Methods 
Chemical and reagents 
Chemicals standards for cocaine (COC), benzoylecgonine (BE), ecgonine methyl esther 
(EME), amphetamine (AMP), methamphetamine (METH), 3,4-methylenedioxy-
methamfetamine (MDMA), methadone (MTD), 2-ethylidene-1,5-dimethyl-3,3-
diphenylpyrrolidine (EDDP), 6-monoacetylmorphine (6-MAM), ketamine (KET), 
norketamine (NK), dehydronorketamine (DHNK), mephedrone, methylenedioxypyrovalerone 
(MDPV), methoxetamine (MXE), butylone, ethylone, methylone, methiopropamine (MPA), 
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4-methoxy-methamphetamine (PMMA), and 4-methoxyamphetamine (PMA) were obtained 
from LGC Standards SARL (Molsheim, France) and Cerilliant (Round Rock, Texas, USA) at 
the concentration of 1 mg/mL or 100 μg/mL in methanol or acetonitrile.  
LC-grade acetonitrile and methanol were purchased from Merck (Darmstadt, Germany). 
Ultrapure water was obtained by purifying demineralized water in an Elga LabWater Purelab 
Flex system (Veolia Water Solutions & Technologies Belgium, Tienen, Belgium). Formic 
acid (eluent additive for LC-MS, 98%) was obtained from Sigma-Aldrich (Steinheim, 
Germany). The internal reference standards ranitidine-D6 and fluoxetine-D5 used (with purity 
> 98%) were purchased from Cerilliant (Round Rock TX, USA) at concentrations of 1 
mg/mL in methanol. Working solutions were prepared for concentrations ranging between 
0.005 - 100 ng/µL in methanol. 
 
Liquid Chromatography 
The LC system consisted of an Agilent Infinity 1290 SL binary pump with an integrated two-
channel solvent degasser, a thermostated Agilent 1290 HiP-ALS autosampler system (20 μL 
injection loop) and a 1290 Agilent TCC SL column compartment (Agilent Technologies, 
Santa Clara, USA). Chromatographic separation was achieved with a Phenomenex Biphenyl 
(100 mm x 2.1 mm, 2.6 μm) column fitted to a SecurityGuard ULTRA Holder for UHPLC 
columns (2.1 - 4.6 mm) and maintained at 32 ºC. Mobile phase composition consisted of 
water (A) and of 80:20 acetonitrile:water (B) both with 0.04% of formic acid, with the 
following gradient: 0 min, 2% B; 2 min, 2% B; 18 min, 40% B; 25 min, 90% B; 29 min, 90% 
B; 29.5 min, 2% B; 33 min, 2% B. The total run time including column equilibration was 33 
min. The injection volume was optimized based on peak shape and set to 2 µL and the flow 
rate was 0.4 mL/min. 
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QTOFMS 
The MS system consisted of an Agilent 6530 Accurate-Mass QTOF instrument (Agilent 
Technologies, Santa Clara, USA) operated with jet stream electrospray ion source (Dual AJS 
ESI source). The source parameters were as follows: gas temperature, 325 °C; gas flow, 8 
L/min; nebulizer gas, 40 psi; sheath gas temperature, 325 °C; sheath gas flow, 11 L/min; 
capillary voltage, 3,500 V and the nozzle voltage, 0 V. The data-independent acquisition 
(All-ions MS/MS) was set-up to acquire three scan segments in MS mode alternating the 
collision energies: 0 eV, 15 eV, and 35 eV, respectively. With this acquisition mode, in only 
one injection data are acquired in scan segment one to display the ‘precursor ion’,  and scan 
segment two and three to provide the product ions. The mass accuracy (within ± 2 ppm) of 
the QTOFMS was calibrated before each analysis using a reference solution for scanning up 
to m/z 1700. The scan range was set to acquire between m/z 50-1000 at a rate of 2.5 spectra/s 
for each scan segment, with a minimum of 12 data points per peak. For measurements, the 
MS was operated in 4 GHz High Resolution mode with a typical resolution of 9000-20000 
full width at half maximum (FWHM) for the mass range m/z 118.0862-622.0289. 
Analyses were performed in positive and negative ESI modes. Mass calibration of the 
QTOFMS system was controlled by constant infusion of a reference mass solution (provided 
by Agilent Technologies) into the source of the QTOFMS system during the analysis. The 
ions selected for recalibrating the mass axis, ensuring the accuracy of mass assignations 
throughout the chromatographic run were the protonated reference ions ([M+H]
+
 =121.0509) 
and [M+H]
+
 =922.0098) for the positive mode and  the deprotonated reference ions ([M-H]
-
 = 
112.9856 and [M-H]
-
 = 980.0164) for negative mode. 
MassHunter software qualitative analysis (Version B.06.00) and the personal compound 
database and library manager (PCDL, Version Rev. B.04.01, Agilent Technologies, Santa 
Clara, USA) were used to develop the data processing workflow. The workflow combines 
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suspect screening [16] and target screening [13,16] techniques for verification and tentative 
identification of compounds.  
 
Samples 
To test the applicability of the workflow, a mix of 20 reference standards in methanol 
with concentrations ranging between 0.12 and 150 ng/mL (Table 1) was prepared and 
injected into the LC-QTOFMS system. We tested anonymized urine and serum samples from 
two different subjects collected at a first aid station during a Belgian dance festival in 2013. 
This study was approved by the Ethical Committee of the Ghent University Hospital (no. 
2013-931) and the participants provided a written informed consent. Details on sample 
preparation are described in the supplementary information.  
 
Data processing workflow 
A- Pre-processing tips 
An exclusion mass list was generated from the acetonitrile blank sample data file and used to 
subtract background noise from the chromatograms. In addition, we monitored consistency of 
our reference masses during a sample run by extracting ion chromatograms (EICs) for the 
reference masses in each chromatogram. 
 
B- In-house library  
PCDL software was used to build an in-house library comprised of molecular formulae, 
retention time (tR) and MS/MS centroid spectra (if reference standards were available). The 
in-house target list was made up of NPS and classical drugs for which analytical reference 
standards were available. In addition, data of extracts containing metabolites derived from 
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laboratory experimental sources (in vitro and in vivo metabolites of some NPS) were acquired 
on the LC-QTOFMS instrument and included as MS/MS centroid spectra.  
The suspect list comprised of NPS from the following groups: cannabinoids, cathinones, 
phenylethylamines, piperazines, tryptamines, opioids, benzodiazepines, plant extracts and 
others (medicinal products, intermediates, precursors and common product ions of known 
compounds). Information was primarily obtained from existing literature on NPS (in vitro 
and in vivo studies), from organizations such as European Early Warning System (EWS), 
European Monitoring Center for Drugs and Drug Addiction (EMCDDA), United Nations 
Office on Drugs and Crime (UNODC) and TICTAC Communications Limited (London) and 
from some few in silico predictions of Phase I and Phase II metabolites. The in silico 
predictions were performed using Meteor Nexus program (Lhasa 145 limited, UK). In 
summary, the library consists of more than 1500 entries. 
 
C- Structuring of identification parameters 
A variety of data processing techniques can be used to extract information from accurate 
mass data. In this work, the identification and scoring system is divided into two parts, one 
for the precursor and another one for the product ion. 
 
‘Precursor ion’ identification  
The molecular formulae in the library are searched against the acquired data using a narrow 
formula matching window of ± 10 ppm. Additionally, it allowed a maximum of 10 possible 
matches per formula as well as the possibility to detect sodium, potassium and ammonium 
adducts in positive mode, plus formic acid adducts in negative mode. The overall match score 
for each candidate species was calculated by the software based on the m/z, molecular 
formula, and isotopic pattern match of > 75% (weights to be specified by the operator: mass-
100%; isotope abundance-60%; isotope spacing-50%; tR-100%).  
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Product ion identification 
The inclusion of product ion confirmation is useful in both cases of target and suspect 
screening. As shown previously [13], the elution profile of precursor and product ions is 
significant in the identification of compounds. In this work, the co-elution profile of each 
candidate accounted for peak shape (symmetry), and the tR difference between precursor ion 
and product ions. 
The product ion identification criteria and specified product ion EIC’s parameters were 
defined as: ± 20 ppm extraction window; S/N > 3; tR window ± 0.1 min of precursor ion; 
overall co-elution score (precursor and product ion correlation) > 80%. To reduce the number 
of qualified product ions, the option to automatically generate formulae for product ions of 
the proposed candidate was included. Qualified product ions for which a possible molecular 
formulae could not be proposed were discarded.   
For the generation of qualified product ions for target compounds (with MS/MS spectra and 
tR in the library), the ten most abundant product ions in the library for the candidate 
compound are extracted as EICs in the acquired data file and overlaid with EIC of the 
precursor ion. Similarly, for suspect compounds (with only molecular formulae in the library) 
20 EICs of the most abundant product ions from average spectra (15 eV and 35 eV) of the 
acquired data file are extracted and overlaid with EIC of the precursor ion.  
In the present work, we used the five levels of identification and confirmation described by 
Schymanski et al. (2014) [16] to communicate the confidence of identification. Confirmation 
by injection of a reference standard for tR, MS and MS/MS spectra were designated as level 
one while with level two a probable structure was proposed based on matching existing 
(library or literature) spectrum data or using non-reported diagnostic MS/MS product ion 
evidence. In the case of level three, a tentative candidate was proposed with a possible 
11 
 
structure, however, the exact structure remained assumed. With a level four, identification of 
a molecular formula was assigned based on the spectral information however, there was 
insufficient evidence to propose possible structure.  Lastly, level five was designated to a 
specific measured accurate mass (m/z) of interest when there was insufficient information to 
assign a formula.  
 
D- Qualified product ion elucidation  
Structures of qualified product ions were elucidated manually using basic fragmentation rules 
and the software ChemDraw Ultra 14.0. At the end of this workflow a list of confirmed 
candidates at different confidence levels is shown.  
 
Results and Discussion  
Compound identification 
The reference standard mixture was useful for confirming the identity of some targeted 
compounds contained in the library (Table 1). It was also useful in assessing the capabilities 
such as the resolving power of the LC-QTOFMS instrument. This aided in setting thresholds 
for algorithm parameters by monitoring % scores for identification of candidate compound, 
and the co-elution profiles of candidate compounds and their product ions. The ideal 
workflow algorithm scores were set to > 75% for parent compound and > 80% for product 
ion identification.  
The proposed workflow (Fig 1) successfully identified and confirmed 90% of the compounds 
in the reference standard mixture (Table 1) within a ± 10 ppm mass tolerance and their 
qualified product ions within ± 20 ppm mass tolerance. For instance, methylone in the 
reference standard mixture had an overall workflow score of 89% which accounted for 
isotopic pattern score of 98% (data not shown), mass error 7.7 ppm, tR of 6.7 min, and 
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qualified product ions with co-elution scores > 90% (Table 1). Since an MS/MS spectrum of 
the candidate compound methylone was included in the library (target compound), the most 
abundant product ions in the library spectra were extracted (EICs) in the data file and 
overlaid with the EIC of the precursor ion (Fig 2). The co-elution score for all four qualified 
product ions was assigned based on predefined criteria for product ions.  
 
When the candidate compound had no MS/MS spectrum in the library (suspect compound), 
the 20 most abundant product ions (with S/N >3; within the specified tR) in the combined 
spectra (collision energies of 15 eV and 35 eV) were extracted as EICs. They were overlaid 
with that of the precursor ion and evaluated based on abundance, peak shape (symmetry), 
peak width and tR (Fig SI-1). A co-elution plot was generated for suspect compounds by 
plotting the normalized ratio of the product to precursor ion abundance over acquisition time 
(Fig SI-1). Following this structural elucidation of the qualified product ions was done to 
deliver a tentative identification and confirmation (Fig SI-1).  
 
Application to samples 
Serum and urine samples from two different subjects were used to assess the applicability of 
the screening workflow. In these two cases, the screening workflow was applied leading to 
the identification and confirmation of ketamine (KET) and 25X-NBOMe and the tentative 
identification of several in silico predicted metabolites (Table 2).  Ketamine was detected in 
the serum sample while 25B-NBOMe and 25C-NBOMe were detected in the urine sample. 
 
Ketamine and metabolites 
KET is closely related to phencyclidine and has been used for its therapeutic value in 
veterinary and human medicine as an anesthetic and analgesic [23, 24]. However, it has also 
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been used as a new psychoactive substance since the 1960s [25,26] and several intoxication 
cases have been reported [25,27]. Some research groups have studied the in vitro metabolism 
of KET [28,27] and identified two major metabolites: norketamine (NK) and 
dehydronorketamine (DHNK). Additionally, these studies [28,27] found several isomers of 
hydroxyketamine (HK) and hydroxynorketamine (HNK). However, the confirmation of these 
metabolites was not done by AMMS. At this point, reference standards for the isomers of 
HNK were not commercially available; however by including chemical formulae of 
metabolites from the literature into our library we were able to tentatively identify six isomers 
of HNK (Table 2) in one of the serum samples. The tentative identification of the three 
detected isomers HNK 1, 2 and 3 (Fig SI-1 and Fig SI-2) was facilitated by the elucidation of 
fragmentation pathways of the qualified product ions, by the possible isomeric structures 
sourced from the literature [28,29] and by in silico predictions from Nexus software. 
Additionally, HNK 4, 5 and 6 were detected based on their accurate mass. However, at very 
low abundances and therefore their isotopic patterns and product ions could not be 
determined, which resulted in a low overall score (Fig 3 and Table 2).  
The product ions at m/z 125.0145 (Δm = -6.4 ppm) and 125.0157 (Δm = 3.2 ppm) were 
labeled as qualified ions for KET and NK, respectively (Table 2). This fragment 
corresponded to the methylbenzene with the chlorine atom ([C7H6Cl]
+
). The presence of a 
chlorine atom was confirmed by the existence of the characteristic chlorine isotopic pattern: 
the abundance of the [M+H+2]
+
 ion was about 1/3
rd
 of the [M+H]
+
 ion. For DHNK (m/z 
222.0676, Δm = -1.8 ppm), three product ions were qualified (Table 2; Fig SI-2). F1 at m/z 
205.0413 (Δm = -1.0 ppm) corresponded to the loss of the amine group from the parent 
compound. Subsequent loss of carbon monoxide moiety lead to F2 at m/z 177.0460 (Δm = -
3.4 ppm) and finally, the loss of a propenal group from the parent compound to F3 at m/z 
170.0717 (Δm = -8.2 ppm) was observed. 
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Seven product ions (HNK 1, F1 to F7) confirmed the presence of HNK 1 (tR 4.75 min) at m/z 
240.0804 (Δm = 7.5 ppm) (Fig SI-1 and Table 2). F1 at m/z 195.0577 (Δm = 3.1 ppm) 
corresponded to the loss of amine and carbon monoxide groups, leading to the formation of a 
double bond or to the formation of a ring. A subsequent loss of a water molecule resulted in 
F2 at m/z 177.0470 (Δm = 2.3 ppm) indicating that the hydroxyl group could not be 
positioned in the aromatic ring. Additional losses of an ethylene moiety and the chlorine atom 
yielded F3 (m/z 151.0306, Δm = -2.0 ppm) and F4 (m/z 142.0768, Δm = -6.3 ppm), 
respectively. F5 corresponded to the common fragment ion at m/z 125.0148 (Δm = -4.0 ppm) 
observed also for KET and NK. Loss of an ethylene group from F4 lead to F6 at m/z 
116.0611 (Δm = -8.6 ppm) and successive cyclization to F7 at m/z 115.0536 (Δm = -5.2 
ppm). Though the position of the hydroxyl group could not be elucidated, it could be in the 
cyclohexanone ring since the loss of water was observed in F2, discarding its possible 
position in the aromatic ring. 
 
In the case of isomer 2 (HNK 2, tR 5.83 min) at m/z 240.0793 (Δm = 2.9 ppm), the presence 
of F1 at m/z 107.0494 corresponding to the molecular formula [C7H7O]
+
 (Δm = -1.9 ppm) 
suggests that the hydroxyl group is positioned in the aromatic ring (see Fig. SI.2). 
HNK 3 (tR 6.12 min) at m/z 240.0786 (Δm = 0.0 ppm) was qualified by three product ions 
(Table 2). F1 at m/z 223.0527 (Δm = 3.1 ppm) corresponded to the loss of ammonia. An 
additional loss of water results in F2 at m/z 205.0418 (Δm = 1.5 ppm). F3 at m/z 142.0769 
(Δm = -5.6 ppm), also observed for HNK 1, resulted from F1 after losing water, the chlorine 
atom and a carbon monoxide moiety (SI-Fig 2). The position of the hydroxyl group might be 
in the cyclohexanone ring since the loss of water was observed in F1, discarding its possible 
position in the aromatic ring. 
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25X-NBOMe and metabolites 
In the NPS market, phenethylamine derivatives account for about 23% of the total number of 
reported NPS between 2009 and 2012 [24]. The 25X-NBOMe series of NPS are classified 
under the ‘2C-substitutes’ of phenylethylamines. This recently emerging group of compounds 
has been detected in several countries [30-32]. Fatal intoxications have been already 
attributed to the parent compounds [33,34]. However, no metabolite biomarkers have been 
identified through in vitro and in vivo studies, and no actual information exists on the best 
biomarkers in urine or serum. Furthermore, there are no commercially available reference 
standards for their metabolites.  
 
Our method was able to confirm presence of 25B-NBOMe (m/z 380.0876, Δm = 5.3 ppm) 
and 25C-NBOMe (m/z 336.1360, Δm = -0.3 ppm) in the sample (Table 2). For 25B-NBOMe 
(C18H22BrNO3), two product ions were qualified at m/z 121.0651 (F1) and 91.0545 (F2) 
corresponding to the methoxymethylbenzene ([C8H9O]
+, Δm = 2.5 ppm) and methylbenzene, 
the tropylium ion ([C7H7]
+, Δm = 3.3 ppm), respectively (Fig 4), yet both product ions are not 
very specific to 25B-NBOMe. The characteristic bromine isotopic pattern with the [M+H+2]
+
 
ion at the same abundance as the [M+H]
+
 ion confirmed the existence of the parent 
compound in the sample. Regarding 25C-NBOMe, it presented the characteristic isotope 
cluster of chlorine and the product ion F1 at m/z 121.0635 (Δm = -10.7 ppm). In the end, both 
compounds were confirmed through the injection of reference standards. 25H-NBOMe at m/z 
302.1778 (Δm = 8.9 ppm), structurally related to 25C-NBOMe and 25B-NBOMe but without 
any halogen substituent, could not be confirmed with any product ion, so its tentative 
identification was only based on its accurate mass, isotopic pattern and molecular formula in 
the spectrum of the precursor ion. 
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The in silico predictions added to our library were useful in the tentative identification of 
some 25B-NBOMe and 25C-NBOMe metabolites in a non-hydrolyzed urine sample (Table 2, 
Fig SI. 3-4). For 25B-NBOMe, Phase I oxidative O-demethylated metabolite (C17H20BrNO3, 
CYP 2b), Phase II N/O-glucuronidated metabolite (C23H29BrNO9, GLU 2a) and O-sulphated 
metabolite (C17H20BrNO6S, SUL 1) along with their product ions were identified (Table 2 
and Fig 4). 25B-NBOMe (CYP 2b) (C17H20BrNO3) at m/z 366.0710 (Δm = 3.0 ppm) differed 
only of 25B-NBOME by 14.018 u due to a methyl group. F1 at m/z 121.0648 (Δm = 0.0 ppm) 
confirmed its presence. The fragments at m/z 121.0709 (Δm = -19.8 ppm) and 121.0656 (Δm 
= 6.6 ppm) were also labelled as qualified product ions of the glucuronidated and sulphated 
conjugate, respectively.  
Additionally, four extra metabolites were identified solely based on the m/z, molecular 
formulae and isotopic pattern thereby confirmed under level four [16] due to lack of qualified 
product ions (Table 2). These metabolites corresponded to another O-demethylation (CYP 
2a), demethylation of both methoxy groups (CYP 1) and two extra glucuronidated conjugates 
(GLU 1 and GLU 3). The errors ranged from 0.4 to 8.1 ppm. Proposed structures for these 
predicted metabolites are shown in Fig SI.3. 
For 25C-NBOMe, the in silico sulphated conjugate was identified at m/z 402.0809 (Δm = 9.0 
ppm). In addition, the fragment at m/z 121.0651 (Δm = -1.7 ppm) was present. The O-
demethylated metabolite (C17H20ClNO3, CYP 1) at m/z 322.1234 (Δm = 9.3 ppm) was also 
identified but no fragments were qualified. Structures of the predicted metabolites are shown 
in Fig SI.4. 
 
Common fragments’ method 
Since NPS are often produced by only small modifications of the chemical structures of 
controlled substances, many of them share structural moieties [35]. Thus, the search for 
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common fragment ions can be performed on the data acquired to identify significant peaks. 
For instance the 25B-NBOMe and its metabolites (Fig 4) have two common fragments (m/z 
121.0648 ([C8H9O]
+
 and m/z 91.0542 ([C7H7]
+
)). EICs generated for 121.0648 from the scan 
segments with collision energies at 15 eV and 35 eV (Fig SI.5) show additional peaks from 
those previously identified that were not included in our suspect list. The additional peaks 
could be significant and can be further analyzed using non-target strategies described by 
Schymanski et al. 2013 [36]. 
Common fragments’ method can be particularly useful when data is acquired using data-
independent acquisition mode since no information (MS and MS/MS) is lost. However, for 
phenylethylamine compounds the common fragment approach is challenging since there are 
many possible modifications to the basic amphetamine/ phenylethylamine structure [37] and 
thus fragments are not so specific and may generate many peaks. 
 
Advantages and challenges of the data-independent acquisition workflow 
Data-dependent acquisition generates MS/MS spectra for pre-selected compounds and may 
miss potential compounds of interest, particularly co-eluting compounds [10]. Since with a 
data-independent method no compounds are pre-selected, all compounds are subject to 
collision induced dissociation including co-eluting compounds. Furthermore, the workflow 
searches the entire library (suspect and target compounds) against the acquired data, which 
allows identification of co-eluting compounds like amphetamine and methiopropamine 
(Table 1). This also indicated that the QTOFMS instrument set to High-Resolution mode (4 
GHz, 10000-15000 resolving power for lower masses) was sufficient to distinguish co-eluting 
analyte ions. Additionally, allowing for multiple matches per formula is useful in the case of 
identification of isomeric compounds at different tR like in the case of ethylone and butylone 
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(Table 1).  Furthermore, it is possible to get the information on the co-elution of analytes 
without additional injections, which is a very difficult task in data-dependent acquisition. 
One of the challenges associated with working in data-independent acquisition mode is the 
difficult association of product ions to a specific precursor ion. Since that precursor ion is not 
previously selected, other ions, even with very different m/z, co-elute and produce a mixed 
spectra. Also, the likelihood of false positives is increased mostly depending on isobaric 
interferences in the matrix. Another potential limitation would be the possibility of isomeric 
compounds co-eluting which would not be easily distinguishable. Lastly, one has to regularly 
update new compounds into the library to keep the suspect list current and avoid missing 
compounds. 
 
Future perspectives  
Detection of NPS is a challenge due to the high number of potential compounds to be 
investigated and their rapid transience in the drug scene. Furthermore, reference standards are 
often not available which makes target analysis impossible. Pooled urine analysis [38,39] and 
analysis of samples from hospital emergency intoxication cases would be useful for detecting 
the occurrence of NPS in order to prioritize the essential NPS for the purchase of reference 
standards. Detection of NPS and their metabolites particularly with a workflow such as the 
one showed in this work would contribute to the identification of possible biomarkers that 
can be applied in the monitoring of community health. Since some substances [40] are 
extensively metabolized, targeting the parent compound may be redundant. In such cases, and 
considering that not much experimental data exist on the biotransformation of NPS, this 
workflow would be useful since it includes screening for not only the parent compounds but 
also potential biomarkers like predicted metabolites. Furthermore, other fields might benefit 
from having biomarker information- such as sewage-based epidemiology [41-44].  
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Conclusions 
In this article we demonstrate the application of data-independent acquisition mode in 
qualitative screening for NPS. The proposed workflow combines two approaches of data 
processing proposed in the literature. Furthermore, we detail the handling of the acquired data 
stressing the importance of precursor and product ion correlation in the tentative 
identification of a suspect compound. Furthermore, the applicability of the workflow in 
distinguishing co-eluting compounds and isomers is demonstrated. The potential use of 
‘common fragments’ approach’ is outlined and the difficulties in identification of 
amphetamine-like compounds are emphasized. The application and significance of in silico 
predicted metabolites is shown, which can be especially useful for NPS detection particularly 
when in vitro and in vivo studies have not been performed. 
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Fig. 1 Illustration of workflow components. FbF- Find By molecular Feature. 
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Fig. 2 Identification of methylone in the reference standard mixture. A) EICs for product ions (m/z 190, 160, 132 and 58) in the library spectrum 
of methylone are extracted from acquired data and overlaid with candidate precursor ion EIC. B) Combined spectra for three scan segments (0, 
15 and 35 eV) at tR 6.88-7.07 min. C) Spectra of the three scan segments at tR 6.97 min. 
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Fig. 3 Chromatogram showing ketamine and its metabolites detected in serum. Six isomers of HNK were detected of which HNK 4, 5 and 6 had 
very low abundance and were identified solely based on their accurate mass.  
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Fig. 4 Proposed fragmentation pathway for 25B-NBOMe and its metabolites detected in a patient’s urine sample. 
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Table 1 Reference standard mix used to set parameter thresholds for the FbF (Find By molecular Feature) algorithm. The workflow scores range 
from 70%- 99% for precursor and product ions. 
a 
Retention time (min); 
b 
m/z measurement error; 
c 
collision energy 
Compound  
a 
tR Ion formula Score Measured m/z  [M+H]
+
 
b Δm (ppm) c CE 
EME 1.13 [C10H18NO3]
+
 99.4 200.1281 0.0 
 EME F1 1.13 [C10H16NO2]
+
 98.8 182.1187 6.0 15 
EME F2 1.13 [C5H8N]
+
 96.8 82.0653 2.4 35 
AMP 5.57 [C9H14N]
+
 93.6 136.1125 2.9 
 AMP F1 5.58 [C7H7]
+
 99.6 91.0546 4.4 35 
AMP F2 5.58 [C3H8N]
+
 95.9 58.0657 10.3 35 
MPA 5.57 [C8H14NS]
+
 97.1 156.0847 3.8 
 MPA F1 5.55 [C5H5S]
+
 99.5 97.0112 6.2 35 
MPA F2 5.58 [C7H7]
+
 94.6 91.0547 5.5 35 
MPA F3 5.58 [C3H8N]
+
 97.3 58.0662 18.9 35 
MPA F4 5.55 [C4H5]
+
 98.3 53.0395 17.0 35 
METH 6.81 [C10H16N]
+
 95.9 150.1274 -2.0 
 METH F1 6.82 [C7H7]
+
 99.7 91.0550 8.8 35 
METH F2 6.80 [C5H5]
+
 97.4 65.0394 12.3 35 
Methylone 6.95 [C11H14NO3]
+
 89.4 208.0984 7.7 
 Methylone F1 6.96 [C11H12NO2]
+
 98.2 190.0868 2.6 15 
Methylone F2 6.96 [C10H10NO]
+
 99.1 160.0762 3.1 15 
Methylone F3 6.96 [C9H10N]
+
 99.2 132.0810 1.5 35 
Methylone F4 6.96 [C3H8N]
+
 98.4 58.0657 10.3 35 
PMA 7.03 [C10H16NO]
+
 79.4 166.1219 -4.2 
 PMA F1 7.04 [C10H13O]
+
 98.4 149.0965 2.7 15 
PMA F2 7.04 [C8H9O]
+
 98.3 121.0654 5.0 15 
PMA F3 7.02 [C7H7]
+
 72.8 91.0548 6.6 35 
DHNK 7.79 [C12H13ClNO]
+
 97.9 222.0676 -1.8 
 DHNK F1 7.78 [C12H10ClO]
+
 98.9 205.0413 -1.0 15 
DHNK F2 7.78 [C11H10Cl]
+
 96.4 177.0460 -3.4 15 
DHNK F3 7.78 [C9H13ClN]
+
 98.4 170.0717 -8.2 35 
6-MAM 7.70 [C19 H22NO4]
+
 76.4 328.156 5.2 
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6-MAM F1 7.70 [C11H12NO]
+
 83.4 174.1234 -2.9 15 
MDMA 7.89 [C11H16NO2]
+
 81.5 194.1193 8.8 
 MDMA F1 7.90 [C10H11O2]
+
 98.9 163.0760 3.7 15 
Ethylone 7.83 [C12H16NO3]
+
 87.8 222.1165 18.0 
 Ethylone F1 7.82 [C12H14NO2]
+
 98.3 204.1041 10.8 15 
Ethylone F2 7.82 [C11H12NO]
+
 99.2 174.0927 8.0 15 
PMMA  8.05 [C11H18NO]
+
 84.8 180.1383 0.0 
 PMMA F1 8.06 [C10H13O]
+
 99.1 149.0971 6.7 15 
PMMA F2 8.06 [C8H9O]
+
 99.5 121.0657 7.4 15 
PMMA F3 8.04 [C7H7]
+
 92.8 91.0550 8.8 35 
PMMA F4 8.04 [C6H6]
+
 97.0 78.0475 14.1 35 
PMMA F5 8.04 [C6H5]
+
 95.1 77.0395 11.7 35 
Mephedrone  8.26 C11H15NO 77.7 178.1241 8.4 
 Mephedrone F1 8.27 C11H14N 99.0 160.1122 0.6 15 
Mephedrone F2 8.27 C10H11N 99.8 145.0879 -4.8 15 
Butylone 8.48 [C12H16NO3]
+
 97.5 222.1128 1.4 
 Butylone F1 8.49 [C11H12NO]
+
 99.3 174.0918 2.9 15 
Butylone F2 8.47 [C7H14O3]
+
 98.9 146.0937 0.0 35 
Butylone F3 8.49 [C6H13O3]
+
 95.5 133.0864 3.8 15 
Butylone F4 8.49 [C4H10N]
+
 99.7 72.0815 9.7 15 
NK 8.84 [C12H15ClNO]
+
 95.6 224.0839 0.9 
 NK F1 8.83 [C7H6Cl]
+
 98.9 125.0169 12.8 40 
Benzoylecgonine  9.54 [C16H20NO4]
+
 81.2 290.1414 9.3 
 Benzoylecgonine F1 9.53 [C9H14NO2]
+
 99.7 168.1024 3.0 15 
Benzoylecgonine F2 9.53 [C7H5O]
+
 99.2 105.0340 4.8 35 
Benzoylecgonine F3 9.53 [C5H8N]
+
 97.4 82.0671 24.4 35 
Benzoylecgonine F4 9.53 [C6H5]
+
 98.7 77.0401 19.5 35 
KET 9.85 [C13H17ClNO]
+
 85.0 238.1001 3.4 
 KET F1 9.84 [C7H6Cl]
+
 99.2 125.0155 1.6 35 
MXE 10.97 [C15H22NO2]
+
 86.3 248.1666 8.5 
 MXE F1 10.98 [C13H15O2]
+
 98.8 203.1073 3.0 15 
MXE F2 10.98 [C8H9O]
+
 98.5 121.066 9.9 35 
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MXE F3 10.98 [C7H7]
+
 99.2 91.0552 11.0 35 
MXE F4 10.98 [C7H7]
+
 85.9 91.0530 -13.2 35 
MDPV 12.34 [C16H22NO3]
+
 95.7 276.1605 4.0 
 COC 12.69 [C17H22NO4]
+
 85.1 304.1584 13.5 
 COC F1 12.70 [C10H16NO2]
+
 70.7 182.1178 1.1 15 
COC F3 12.70 [C7H5O]
+
 72.9 105.0340 4.8 35 
COC F2 12.70 [C5H8N]
+
 70.6 82.0661 12.2 35 
EDDP 19.05 [C20H24N]
+
 93.7 278.1916 4.7 
 EDDP F1 19.04 [C17H16N]
+
 98.8 234.1288 4.7 35 
MTD 19.95 [C21H28NO]
+
 84.8 310.2188 7.4 
 MTD F1 19.96 [C19H21O]
+
 98.2 265.1616 10.9 15 
MTD F2 19.96 [C7H5O]
+
 98.7 105.0359 22.8 35 
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Table 2 Compounds detected in serum and urine samples.
 a 
Retention time (min); 
b 
m/z measurement error; 
c
 collision energy; 
d
 Identification 
level according to Schymanski et. al (2014) 
 
Compound  tR
 a
 Ion formula Score Measured m/z 
b Δm 
(ppm) 
c
 CE 
Confirmation 
Level 
d
 (1-5) 
Serum sample (patient one) 
KET  9.63 [C13H17ClNO]
+
 93.9 238.0998 2.1 
 
1 
KET F1 9.64 [C7H6Cl]
+
 98.9 125.0145 -6.4 35 1 
NK 8.67 [C12H15ClNO]
+
 79.7 224.0832 -2.2 
 
1 
NK F1 8.66 [C7H6Cl]
+
 99.6 125.0157 3.2 35 1 
DHNK 7.79 [C12H13ClNO]
+
 97.9 222.0676 -1.8 
 
1 
DHNK F1 7.78 [C12H10ClO]
+
 98.9 205.0413 -1.0 15 1 
DHNK F2 7.78 [C11H10Cl]
+
 96.4 177.0460 -3.4 15 1 
DHNK F3 7.78 [C9H13ClN]
+
 98.4 170.0717 -8.2 35 1 
HNK 1 4.75 [C12H15ClNO2]
+
 86.9 240.0804 7.5 
 
3 
HNK  1 F1 4.76 [C11H12ClO]
+
 97.8 195.0577 3.1 15 3 
HNK  1 F2 4.76 [C11H10Cl]
+
 97.7 177.0470 2.3 15 3 
HNK  1 F3 4.76 [C9H8Cl]
+
 99.1 151.0306 -2.0 35 3 
HNK  1 F4 4.74 [C11H10]
+
 97.6 142.0768 -6.3 35 3 
HNK  1 F5 4.74 [C7H6Cl]
+
 98.8 125.0148 -4.0 35 3 
HNK  1 F6 4.74 [C9H8]
+
 97.8 116.0611 -8.6 35 3 
HNK  1 F7 4.74 [C9H7]
+
 97.3 115.0536 -5.2 35 3 
HNK  2 5.83 [C12H15ClNO2]
+
 87.4 240.0793 2.9 
 
3 
HNK  2 F1 5.76  [C7H7O]
+
 81.3 107.0494 -1.9 35 3 
HNK  3 6.12 [C12H15ClNO2]
+
 96.3 240.0786 0.0 
 
3 
HNK  3 F1 6.11 [C12H12ClO2]
+
 97.2 223.0527 3.1 15 3 
HNK  3 F2 6.11 [C12H10ClO]
+
 98.0 205.0418 1.5 15 3 
HNK  3 F3 6.11 [C11H10]
+
 96.1 142.0769 -5.6 35 3 
HNK 4 4.04 [C12H15ClNO2]
+
 47.0 240.0792 2.5 
 
5 
HNK 5 3.53 [C12H15ClNO2]
+
 47.2 240.0772 -5.8 
 
5 
HNK 6 7.67 [C12H15ClNO2]
+
 45.6 240.0799 5.4 
 
5 
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Urine sample (patient two) 
25B-NBOMe 19.40 [C18H23BrNO3]
+
 83.6 380.0876 5.3 
 
1 
25B-NBOMe F1 19.41 [C8H9O]
+
 99.3 121.0651 2.5 15 1 
25B-NBOMe F2 19.41 [C7H7]
+
 92.3 91.0545 3.3 35 1 
25B-NBOMe (GLU 1) 12.37 [C23H29BrNO10]
+
 81.9 558.0977 1.4 
 
4 
25B-NBOMe (GLU 2a) 13.69 [C23H29BrNO9]
+
 88.2 542.1024 0.7 
 
3 
25B-NBOMe (GLU 2a) F1 13.68 [C4H11NO3]
+
 73.0 121.0709 -19.8 
 
3 
25B-NBOMe (GLU 2b) 13.88 [C23H29BrNO9]
+
 96.9 542.1022 0.4 
 
4 
25B-NBOMe (CYP 1) 13.98 [C16H19BrNO3]
+
 74.8 352.0572 8.2 
 
4 
25B-NBOMe (GLU 3) 14.53 [C24H31BrNO10]
+
 90.3 572.1134 1.4 
 
4 
25B-NBOMe (SUL 1) 15.61 [C17H21BrNO6S]
+
 93.1 446.0281 3.1 
 
3 
25B-NBOMe (SUL 1) F1 15.60 [C8H9O]
+
 90.0 121.0656 6.6 35 3 
25B-NBOMe (CYP 2a) 16.22 [C17H21BrNO3]
+
 81.8 366.0710 3.0 
 
4 
25B-NBOMe (CYP 2b) 16.56 [C17H21BrNO3]
+
 98.8 366.0698 -0.3 
 
3 
25B-NBOMe (CYP 2b)  F1 16.55 [C8H9O]
+
 97.3 121.0648 0.0 35 3 
25C-NBOMe 18.77 [C18H23ClNO3]
+
 84.7 336.1360 -0.3 
 
1 
25C-NBOMe F1 18.78 [C8H9O]
+
 92.4 121.0635 -10.7 15 1 
25C-NBOMe (SUL 1) 15.18 [C17H21ClNO6S]
+
 70.1 402.0809 9.0 
 
3 
25C-NBOMe (SUL 1) F1 15.17 [C8H9O]
+ 
99.3 121.0651 -1.7 35 3 
25C-NBOMe (CYP 1) 15.84 [C17H21ClNO3]
+
 81.3 322.1234 9.3  4 
25H-NBOMe 5.13 [C18H24NO3]
+
 77.0 302.1778 8.9  4 
 
 
